How β3 -adrenoceptor-selective is mirabegron?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity.The Journal of clinical investigation · 2020
   Trial
2. Target and off-target effects of vibegron on smooth muscle contraction of human detrusor and prostate tissues.Naunyn-Schmiedeberg's archives of pharmacology · 2026
   Article
3. Project-Based Public-Private Collaborations.Handbook of experimental pharmacology · 2024
   Review
4. βBritish journal of pharmacology · 2019
   Review
5. Mirabegron: potential off target effects and uses beyond the bladder.British journal of pharmacology · 2018
   Review
6. On the Site and Mechanism of Action of βInternational neurourology journal · 2017
   Review
7. How β3 -adrenoceptor-selective is mirabegron?British journal of pharmacology · 2016
   Article

Corrections and comments

• Comment on
  Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade.2016

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as